Cover Image
市場調查報告書

HER-2陽性乳癌的美國市場:2015-2019年

HER-2 Positive Breast Cancer Market in the US 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 326321
出版日期 內容資訊 英文 108 Pages
訂單完成後即時交付
價格
Back to Top
HER-2陽性乳癌的美國市場:2015-2019年 HER-2 Positive Breast Cancer Market in the US 2015-2019
出版日期: 2015年03月18日 內容資訊: 英文 108 Pages
簡介

根據GLOBOCAN的報告,2012年的乳癌患者數佔癌症患者數整體的11.9%,全球死亡數上升到522,000件。HER-2陽性乳癌佔著乳癌患者數整體約25%。美國的HER-2陽性乳癌的市場,從2014年到2019年,以12.65%的年複合成長率成長

本報告提供HER-2陽性乳癌的治療所採用藥物的美國市場相關調查、HER-2陽性乳癌概要、診斷法、疾病管理、治療方法種類與概要、治療方法及各藥物類型、分子類型、給藥途徑的市場規模的變化與預測、市場成長的各種影響因素分析、主要藥物的評估、競爭環境及市場佔有率、主要經營者簡介等彙整資料。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 疾病概要

  • 關於疾病
  • 病理生理學
  • 疾學問
  • 診斷
    • 免疫組織化學檢驗
    • FISH法
    • SPoT-Light HER2 CISH檢驗 (Subtraction Probe Technology Chromogenic In Situ Hybridization檢驗)
    • Inform HER2 Dual ISH檢驗 (Inform Dual In Situ Hybridization檢驗)
  • 疾病管理
    • 手術
    • 放射治療
    • 化療
    • 標靶治療
    • 荷爾蒙療法
  • 經濟負擔

第7章 市場環境

  • 市場概要
  • 市場規模、預測
  • 波特的五力分析

第8章 各治療、藥物類型市場

  • 化療
    • 甲醇烷基化藥
    • 代謝拮抗劑
    • 細胞毒性抗生素
    • 紫杉烷類
  • 標靶治療
  • 荷爾蒙療法

第9章 各分子類型市場

  • 生物製藥
  • 小分子

第10章 各給藥途徑市場

  • 口服
  • 非口服

第11章 購買標準

第12章 推動市場成長要素

第13章 成長推動因素與其影響

第14章 市場課題

第15章 成長推動因素與課題的影響

第16章 市場趨勢

第17章 趨勢與其影響

第18章 業者情勢

  • 競爭模式
    • 主要新聞
    • M&A
  • 市場佔有率分析
    • 主要藥物的競爭評估
    • Celgene
    • F. Hoffmann-La Roche
    • GlaxoSmithKline
    • Novartis
    • Sanofi
  • 其他主要供應商

第19章 主要供應商分析

  • Celgene
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Novartis
  • Sanofi
    • 主要資料
    • 產業概要
    • 各部門的市場收益
    • 各地區的市場收益
    • 產業策略
    • 最近的發展趨勢
    • SWOT分析等

第20章 相關報告

圖表

目錄
Product Code: IRTNTR5344

About HER-2 Positive Breast Cancer

Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated carcinoma. Breast cancer is the second most common form of cancer in women. HER-2 is a protein that affects the growth of malignant cells and is usually found on the surface of normal breast cells. Sometimes, a large number of HER-2 receptors are found on the surface of breast cancer cells. These HER-2 receptors are responsible for stimulating the growth and division of malignant cancerous cells. This condition is therefore known as HER-2 positive breast cancer. HER-2 positive breast cancers have a tendency to spread and metastasize more rapidly than HER-2 negative breast cancers. HER-2 positive breast cancer is more prevalent in females than males. In 2012, GLOBOCAN reported that breast cancer accounted for 11.9 percent of the total number of cancer cases and led to 522,000 deaths worldwide. HER-2 positive breast cancer accounts for almost 25 percent of all types of breast cancer.

TechNavio's analysts forecast the HER-2 Positive Breast Cancer market in US to grow at a CAGR of 12.65 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the HER-2 Positive Breast Cancer market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of targeted therapeutics and chemotherapeutics used in the management of HER-2 positive breast cancer patients.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the HER-2 Positive Breast Cancer market in the US. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, HER-2 Positive Breast Cancer Market in US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape of the HER-2 Positive Breast Cancer market in the US and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors

  • Celgene
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Novartis
  • Sanofi

Other Prominent Vendors

  • Bristol-Myers Squibb
  • DARA BioSciences
  • Eisai
  • Hospira
  • Pfizer
  • ProStrakan
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical

Market Driver

  • Increase in Population of Breast Cancer Patients
  • For a full, detailed list, view our report

Market Challenge

  • Poor Diagnosis and Screening
  • For a full, detailed list, view our report

Market Trend

  • Increase in Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Understanding the Disease
  • 06.2. Pathophysiology
  • 06.3. Epidemiology
  • 06.4. Diagnosis
    • 06.4.1. IHC
    • 06.4.2. FISH
    • 06.4.3. SPoT-Light HER-2 CISH Test (Subtraction Probe Technology Chromogenic In Situ Hybridization)
    • 06.4.4. Inform HER-2 Dual ISH Test (Inform Dual In Situ Hybridization)
  • 06.5. Management
    • 06.5.1. Surgery
    • 06.5.2. Radiotherapy
    • 06.5.3. Chemotherapy
    • 06.5.4. Targeted Therapy
    • 06.5.5. Hormonal Therapy
  • 06.6. Economic Burden

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Market Segmentation by Type of Therapy

  • 08.1. Chemotherapy
    • 08.1.1. Alkylating Agents
    • 08.1.2. Antimetabolites
    • 08.1.3. Cytotoxic Antibiotics
    • 08.1.4. Taxanes
  • 08.2. Targeted Therapy
  • 08.3. Hormone Therapy

09. 9. Market Segmentation by Molecule Type

  • 09.1. Biologics
  • 09.2. Small Molecules

10. Market Segmentation by Route of Administration

  • 10.1. Oral
  • 10.2. Parenteral

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2014
    • 18.2.1. Competitive Assessment of the Top Drugs
    • 18.2.2. Celgene
    • 18.2.3. F. Hoffmann-La Roche
    • 18.2.4. GlaxoSmithKline
    • 18.2.5. Novartis
    • 18.2.6. Sanofi
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Celgene
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Business Strategy
    • 19.1.4. Business Segmentation by Revenue
    • 19.1.5. Sales by Geography
    • 19.1.6. Key Information
    • 19.1.7. SWOT Analysis
  • 19.2. F. Hoffmann-La Roche
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Business Segmentation
    • 19.2.4. Business Segmentation by Revenue 2012 and 2013
    • 19.2.5. Sales by Geography
    • 19.2.6. Business Strategy
    • 19.2.7. Key Information
    • 19.2.8. SWOT Analysis
  • 19.3. GlaxoSmithKline
    • 19.3.1. Key Facts
    • 19.3.2. Business Overview
    • 19.3.3. Business Segmentation
    • 19.3.4. Business Segmentation by Revenue 2012 and 2013
    • 19.3.5. Sales by Geography
    • 19.3.6. Pipeline Products
    • 19.3.7. Business Strategy
    • 19.3.8. Key Information
    • 19.3.9. SWOT Analysis
  • 19.4. Novartis
    • 19.4.1. Key Facts
    • 19.4.2. Business Description
    • 19.4.3. Business Segmentation
    • 19.4.4. Revenue by Business Segmentation
    • 19.4.5. Revenue Comparison 2012 and 2013
    • 19.4.6. Sales by Geography
    • 19.4.7. Business Strategy
    • 19.4.8. Key Developments
    • 19.4.9. SWOT Analysis
  • 19.5. Sanofi
    • 19.5.1. Key Facts
    • 19.5.2. Business Description
    • 19.5.3. Business Segmentation
    • 19.5.4. Revenue by Business Segmentation
    • 19.5.5. Revenue Comparison 2012 and 2013
    • 19.5.6. Sales by Geography
    • 19.5.7. Business Strategy
    • 19.5.8. Key Developments
    • 19.5.9. SWOT Analysis

20. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Pathophysiology of HER-2 Positive Breast Cancer
  • Exhibit 3: Prevalence of HER-2 Positive Breast Cancer in US 2014
  • Exhibit 4: Prevalence of HER-2 Positive Breast Cancer in US 2014 (in percentage)
  • Exhibit 5: IHC: Diagnosis of HER-2 Positive Breast Cancer
  • Exhibit 6: FISH: Diagnosis of HER-2 Positive Breast Cancer
  • Exhibit 7: Management of HER-2 Positive Breast Cancer
  • Exhibit 8: ASCO Treatment Guidelines for HER-2 Positive Breast Cancer
  • Exhibit 9: Snapshot of Economic Burden of HER-2 Positive Breast Cancer Market in US
  • Exhibit 10: Snapshot of HER-2 Positive Breast Cancer Market in US 2014
  • Exhibit 11: HER-2 Positive Breast Cancer Market in US 2014-2019 (US$ million)
  • Exhibit 12: Drivers and Challenges of HER-2 Positive Breast Cancer Market in US
  • Exhibit 13: Segmentation of HER-2 Positive Breast Cancer Market in US by Type of Therapy
  • Exhibit 14: Segmentation of HER-2 Positive Breast Cancer Market in US by Type of Therapy 2014
  • Exhibit 15: Segmentation of HER-2 Positive Breast Cancer Market in US by Molecule Type
  • Exhibit 16: Segmentation of HER-2 Positive Breast Cancer Market in US by Molecule Type 2014
  • Exhibit 17: Segmentation of HER-2 Positive Breast Cancer Market in US by Route of Administration
  • Exhibit 18: Segmentation of HER-2 Positive Breast Cancer Market in US by Route of Administration 2014
  • Exhibit 19: Buying Criteria of HER-2 Positive Breast Cancer Market in US
  • Exhibit 20: Drivers and their Impact on Key Customer Category of HER-2 Positive Breast Cancer Market in US
  • Exhibit 21: Five-year Survival Rate by Stage of Diagnosis (SEER Analysis for 2004-2010)
  • Exhibit 22: Revenue Comparison of Top Drugs for HER-2 Positive Breast Cancer 2013 (US$ million)
  • Exhibit 23: Celgene: Product Portfolio
  • Exhibit 24: Abraxane: YoY Growth Rate and Global Revenue 2010-2013 (US$ million)
  • Exhibit 25: F. Hoffmann-La Roche: Product Portfolio
  • Exhibit 26: Herceptin: YoY Growth Rate and Revenue 2010-2013 (US$ million)
  • Exhibit 27: Perjeta: Revenue 2012 and 2013 (US$ million)
  • Exhibit 28: Xeloda: YoY Growth Rate and Revenue 2010-2013 (US$ million)
  • Exhibit 29: GlaxoSmithKline: Product Portfolio
  • Exhibit 30: Tykerb: YoY Growth Rate and Revenue 2010-2013 (US$ million)
  • Exhibit 31: Novartis: Product Portfolio
  • Exhibit 32: Femara: YoY Growth Rate and Revenue 2010-2013 (US$ million)
  • Exhibit 33: Sanofi: Product Portfolio
  • Exhibit 34: Taxotere: YoY Growth Rate and Global Revenue 2010-2013 (US$ million)
  • Exhibit 35: Celgene: Business Segmentation by Revenue 2011-2013 (US$ million)
  • Exhibit 36: Celgene: Sales by Geography 2013
  • Exhibit 37: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
  • Exhibit 38: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 39: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 40: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 41: GlaxoSmithKline: Business Segmentation 2013
  • Exhibit 42: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 43: GlaxoSmithKline: Sales by Geography 2013
  • Exhibit 44: GlaxoSmithKline: Pipeline Products 2013
  • Exhibit 45: Novartis AG: Business Segmentation
  • Exhibit 46: Novartis AG: Revenue by Business Segmentation 2013
  • Exhibit 47: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 48: Novartis AG: Revenue by Geographical Segmentation 2013
  • Exhibit 49: Sanofi SA: Business Segmentation
  • Exhibit 50: Sanofi SA: Revenue by Business Segmentation 2013
  • Exhibit 51: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 52: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
Back to Top